Full Text View
Tabular View
No Study Results Posted
Related Studies
Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
This study is currently recruiting participants.
Verified November 2011 by University of Heidelberg
Study NCT01426633   Information provided by University of Heidelberg

First Received on August 29, 2011.   Last Updated on November 29, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leiomyosarcoma
Liposarcoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Adipose Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms, Muscle Tissue
Sarcoma
Interventions listed in this trial
Gemcitabine + Trabectedin
Additional drug interventions recognized in this trial
Gemcitabine
Trabectedin
More general drug interventions related to this trial
Alkylating Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
University of Heidelberg


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services